52-week range
Price risk
Balance sheet & cash
What is the price implying?
Trailing earnings per share are negative, so a P/E-based figure does not exist. See the loss-makers list on the Expectations Gap page for a revenue-based version.
“Implied growth” is what the current price would require under our stated assumptions, not what we expect.
What changed?
- Oct '26Fell 40% from the Sep 2026 peak to the Oct 2026 low.
- Oct '26Volume reached 10.9x its 50-day median on 2026-10-05; price -5.0% that day.
- Sep '26Regained the 2025-09 peak, 6 months after the low.
- Sep '26FII + DII holding fell 3.9 pts over 2 quarters to 4.4%.
- Sep '26Volume reached 31.9x its 50-day median on 2026-09-24; price +4.6% that day.
- Jun '26Debt / equity rose above 1.0x (1.17x).
- Apr '26Volume reached 21.6x its 50-day median on 2026-04-21; price +1.3% that day.
- Mar '26Fell 52% from the Sep 2025 peak to the Mar 2026 low.
Show 3 earlier events
- Jan '26Volume reached 10.7x its 50-day median on 2026-01-28; price +12.4% that day.
- Dec '25FII + DII holding fell 7.1 pts over 1 quarter to 11.7%.
- Dec '25Volume reached 6.6x its 50-day median on 2025-12-10; price +6.2% that day.
Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.
Where price and fundamentals disagree, market-wide Rewind the whole market to any month
Are profits backed by cash?
1 of 2 checks are within range, 1 beyond a threshold.
Tap a check to see how it is measured.
Other income reliance—Not enough data
Not enough reported data to compute this.
Tax rate—Not enough data
Not enough reported data to compute this.
Cash conversion—Not enough data
Not enough reported data to compute this.
Free cash flow1 of 3 yrsBeyond threshold
Fiscal years with positive free cash flow in the last 3: 1. Bands: at least 80% of years, 40% to 80%, below 40%.
Receivable days vs history—Not enough data
Not enough reported data to compute this.
Capital work in progress0% of fixed assetsWithin range
Capital work-in-progress is 0% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.
Payable days—Not enough data
Not enough reported data to compute this.
How to read this
Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.
Who has been buying and selling?
- Since Jun 2025, DIIs trimmed 8.3 pts; FIIs trimmed 6.1 pts.
- The number of shareholders fell from 2.3 lakh to 2.2 lakh (-5%) between Jun 2025 and Jun 2026.
Holdings, Jun '26
How each group changed
Number of shareholders
Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.
How rough has the ride been?
Monthly share price
Last 90 trading days
Drawdown from peak
Largest drawdowns
-51.8% (2025-09 peak to 2026-03 low, recovered 2026-09)
-40.4% (2026-09 peak to 2026-10 low, not yet recovered)
Most recent volume spikes
2026-10-13: 5.2x the 50-day median, price -4.5% that day
2026-10-08: 5.8x the 50-day median, price -2.8% that day
2026-10-06: 5.1x the 50-day median, price +5.0% that day
What else looks like this?
Companies with the most similar financial profile today, regardless of industry.
| Company | Sector | Similarity | Closest on |
|---|---|---|---|
| CAMLIN FINE SCIENCES (CAMLINFINE) | Process Industries | 70% | market cap, operating margin |
| WALCHANDNAGAR INDUSTRIES (WALCHANNAG) | Producer Manufacturing | 57% | ROCE, market cap |
| ASIAN GRANITO INDIA (ASIANTILES) | Producer Manufacturing | 45% | ROCE, operating margin |
| NACL INDUSTRIES (NACLIND) | Process Industries | 44% | market cap, volatility |
| DISHMAN CARBOGEN AMCIS (DCAL) | Health Technology | 35% | market cap, ROCE |
Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.
What happened next to similar setups
- We found 50 past situations where a non-financial company looked like STL NETWORKS LIMITED today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
- Over the following 12 months the middle half of them returned −37% to +14% vs the market, against −3% for all non-financial companies in the same months.
- The analogs' median sat below that base rate (gap −13.0%, 80% range −26.9% to −4.3%), but the matches cluster in only 6 distinct 12-month windows.
Where the 50 outcomes landed
Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 6 beyond the range shown, drawn at the edge
50 past situations · 50 companies · 40 months · 2020–2025
The closest matches
| Company | When | P/E | ROCE | 12M mom. | Drawdown | Next 12 months |
|---|---|---|---|---|---|---|
| SANGHIIND Non-Energy Minerals |
Oct 2023 | — | -3% | +112% | −11% | −50% |
| DCW Process Industries |
Jun 2025 | — | 1% | +52% | −24% | −44% |
| WALCHANNAG Producer Manufacturing |
Jun 2024 | — | 0% | +181% | −10% | −6% |
| DWARKESH Process Industries |
Dec 2022 | — | — | +47% | −26% | −35% |
| GANESHHOU Finance |
Jun 2021 | — | -4% | +212% | −10% | +170% |
Show the other 3 matches
| Company | When | P/E | ROCE | 12M mom. | Drawdown | Next 12 months |
|---|---|---|---|---|---|---|
| JAYNECOIND Producer Manufacturing |
Feb 2024 | — | 3% | +138% | −16% | −38% |
| WOCKPHARMA Health Technology |
Jan 2024 | — | 0% | +123% | −7% | +185% |
| SPECIALITY Consumer Services |
May 2022 | — | -8% | +134% | −28% | +88% |
How reliable is this?
Matched on P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: interest cover, ROCE and P/S. Not used (unavailable for this company): P/E. This company is loss-making, so it was only compared with loss-making companies. One match per company and at most 7 from any one month.
Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.
Monthly history (14 months)
| Month | Revenue (TTM) | ROE | ROCE | Debt / Equity |
|---|---|---|---|---|
| 2026-10 | ₹945 cr | -12.4% | 0.0% | 1.2x |
| 2026-09 | ₹945 cr | -12.4% | 0.0% | 1.2x |
| 2026-08 | ₹959 cr | -12.4% | 0.0% | 1.2x |
| 2026-07 | ₹959 cr | -12.4% | 0.0% | 1.2x |
| 2026-06 | ₹959 cr | -12.4% | 0.0% | 1.2x |
| 2026-05 | ₹937 cr | -8.0% | 4.0% | 0.9x |
| 2026-04 | ₹937 cr | -8.0% | 4.0% | 0.9x |
| 2026-03 | ₹937 cr | -8.0% | 4.0% | 0.9x |
| 2026-02 | ₹890 cr | -8.7% | 4.0% | 0.9x |
| 2026-01 | ₹890 cr | -8.7% | 4.0% | 0.9x |
| 2025-12 | ₹890 cr | -8.7% | 4.0% | 0.9x |
| 2025-11 | ₹1016 cr | -6.1% | 4.0% | 0.9x |
| 2025-10 | ₹1016 cr | -6.1% | 4.0% | 0.9x |
| 2025-09 | ₹1016 cr | -6.1% | 4.0% | 0.9x |